The immune system may interplay between Chlamydia pneumoniae infection and coronary artery disease (CAD). Major histocompatibility complex genes regulate innate and adaptive immunity. Patients with CAD (n ‫؍‬ 100) and controls (n ‫؍‬ 74) were enrolled. Human leukocyte antigens (HLA-A, HLA-B, and HLA-DRB1), four lymphotoxin alpha single-nucleotide polymorphisms, and complement C4A and C4B allotypes were typed, and their haplotypes were inferred. The presence of serum C. pneumoniae immunoglobulin A (IgA) (titer, >40) or IgG (titer, >128) antibodies or immune complex (IC)-bound IgG antibodies (titer, >2) was considered to be a serological marker suggesting chronic C. pneumoniae infection. C. pneumoniae IgA antibodies were found more frequently in patients than in controls (P ‫؍‬ 0.04). Among the patients, multiple logistic regression analysis showed the HLA-B*35 allele to be the strongest-risk gene for C. pneumoniae infection (odds ratio, 7.88; 95% confidence interval, 2.44 to 25.43; P ‫؍‬ 0.0006). Markers of C. pneumoniae infection were found more frequently in patients with the HLA-A*03-B*35 haplotype than in those without the haplotype (P ‫؍‬ 0.007 for IgA; P ‫؍‬ 0.008 for IgG; P ‫؍‬ 0.002 for IC). Smokers with HLA-B*35 or HLA-A*03-B*35 had markers of C. pneumoniae infection that appeared more often than in smokers without these genes (P ‫؍‬ 0.003 and P ‫؍‬ 0.001, respectively). No associations were found in controls. In conclusion, HLA-B*35 may be the link between chronic C. pneumoniae infection and CAD.
Atherosclerosis is a chronic inflammatory process (11) in which infections, especially those caused by Chlamydia pneumoniae (24, 35) , have been suggested to play a role. C. pneumoniae is a common cause of respiratory tract infections. Like all chlamydial species, it has a tendency to cause chronic infections. This may lead to severe sequelae such as chronic obstructive pulmonary disease (42) and cardiovascular diseases (24) . Most likely, all individuals get infected with C. pneumoniae during their lifetimes, but many of them are capable of resolving the infection, and only some become chronically infected. It is assumed that in order to maintain a persistent infection and to evade host defense mechanisms, chlamydiae have developed specific strategies (9) , e.g., by being an obligatory intracellular organism and by having a unique and complicated life cycle (21) . An aberrant and persistent form of C. pneumoniae can be induced by gamma interferon (31) , antibiotics (7) , and tobacco smoke (44) in in vitro cell cultures. In vivo, however, immunogenetic factors (22) of the host also contribute to the infection outcome.
The major histocompatibility complex (MHC) region takes part in innate and adaptive immunity (28) . MHC molecules present microbial peptides to the appropriate subsets of T cells. Patients with specific HLA genes are susceptible or re-sistant to certain viral and nonviral pathogens (12, 32) . Immunoglobulin A (IgA) and IgG antibodies against C. pneumoniae (35) and immune complexes (ICs) (23, 25) have frequently been found to be present in sera of patients with coronary artery disease (CAD). Recently, we showed that HLA-B*35and DRB1*01-related haplotypes are found more frequently in patients with CAD than in healthy age-and sex-matched controls. Also, smokers who had a complement component C4B null allele together with HLA-DRB1*01 were shown to be prone to cardiovascular disease (30) . Therefore, in this study, we assessed MHC genes associated with serological markers of C. pneumoniae infection, elevated specific IgA and IgG antibody levels and the presence of specific circulating ICs, in patients with CAD.
MATERIALS AND METHODS

Study subjects.
Patients with CAD (n ϭ 148) were recruited from nine different central hospitals in Finland between September 1998 and December 2000, as described previously (39) . The inclusion criteria for the patients were as follows. Patients had to have clear symptoms of angina with electrocardiographic evidence of myocardial ischemia. Patients who met the anginal pain inclusion criteria but none of the electrocardiographic criteria were eligible to enter the trial if their cardiac enzymes were consistent with the occurrence of myocardial infarction. Patients with prolonged chest pain with electrocardiogram changes indicating either unstable angina (n ϭ 43) or non-Q-wave myocardial infarction (n ϭ 105) were enrolled. No differences in the C. pneumoniae infection markers between the patients with unstable angina and non-Q myocardial infarction were found (data not shown). The original study was a placebo-controlled study on clarithromycin treatment of patients with acute coronary syndrome (ACS) (39) . For the MHC gene study, we randomly selected 100 of the patients. No differences in the C. pneumoniae infection markers studied were found between the patients receiving study medication and placebo (data not shown). Blood samples from patients were taken at the time of hospitalization (visit 1) and 1 week (visit 2), 3 months (visit 3), and 1 year (visit 4) after hospital admission. Consecutive age-and sex-matched healthy blood donors (n ϭ 74) served as controls and donated a blood sample once. The criteria for blood donation are available at http://www.veripalvelu.redcross.fi/.
Baseline characteristics of the patients and controls are shown in Table 1 . All patients and controls gave written informed consent. Study protocols were approved by local ethics committees.
Laboratory procedures. Genomic HLA-A, HLA-B, and HLA-DRB1 tissue typing, four lymphotoxin alpha (LTA) single-nucleotide polymorphisms (positions ϩ253 [a/g], ϩ496 [C/T], ϩ633 [c/g], and ϩ724 [C/A]), and complement C4A and C4B allotyping were performed (lowercase indicates intronic and uppercase indicates exonic variation). MHC haplotypes of the subjects were inferred using all these markers (30) .
Sera were tested for C. pneumoniae-specific IgA and IgG antibodies by the microimmunofluorescence method using elementary bodies of Kajaani 6 as antigens (43) . Fourfold serum dilutions were used, starting from 1/32 for IgG and 1/10 for IgA, as described previously (13, 14) . Isolation of C. pneumoniae-specific ICs was performed by polyethylene glycol precipitation, and IgG antibodies against C. pneumoniae were measured from dissociated ICs by microimmunofluorescence at twofold dilutions starting from a dilution of 1/2, as described previously (13, 25) .
Due to the lack of information on controls' smoking statuses, we measured plasma cotinine levels by use of a gas chromatograph equipped with a nitrogen phosphorous detector. The cutoff point for the classification of active smoking was set at 10 ng/ml (1), revealing subjects who had smoked tobacco within a week.
Statistical analysis. For this study, elevated levels of antichlamydial IgA (titer, Ն40) or IgG (titer, Ն128) or the presence of IC-bound antichlamydial IgG antibodies (titer, Ն2) at any visit was considered to be a marker of C. pneumoniae infection, suggesting persistent infection (14) . Positivity with any of these three titers was considered to be positivity for C. pneumoniae infection. The correlation between C. pneumoniae infection and CAD was examined by comparing C. pneumoniae infection markers in patients and controls. The potential association between MHC genes and C. pneumoniae infection markers was examined as follows.
Forward stepwise multiple-logistic regression analysis was used to study the association between alleles (HLA-A, HLA-B, LTAϩ253a/g, LTAϩ496C/T, LTAϩ633c/g, LTAϩ724C/A, C4A, C4B, and HLA-DRB1) and any of the markers of C. pneumoniae infection. Categorical data were compared by the chisquare or Fisher's exact test to study whether the frequencies of C. pneumoniae infection markers differed in patients with and those without the MHC alleles.
Data were analyzed using SPSS 12.0.1 (SPSS Inc., Chicago, IL). For all statistical tests, a P value of Ͻ0.05 was considered to be statistically significant.
RESULTS
Baseline characteristics of patients with ACS (n ϭ 100) and controls (n ϭ 74) are shown in Table 1 . C. pneumoniae titers for both patients and controls ranged between 5 and 640 for IgA, 16 and 2,048 for IgG, and 1 and 32 for IC. Patients were C. pneumoniae seropositive more often than controls ( Table 2) .
In univariate analyses, any single marker (IgA titer of Ն40, IgG titer of Ն128, or IC titer of Ն2) of C. pneumoniae infection was found more frequently in the patients with the haplotypes HLA-A*03-B*35 and HLA-A*03-B*35-LTAϩ724C Controls filled the questionnaire formatted by the Blood Transfusion Service before blood donation. Any of these clinical conditions are severe enough for the need of medication, and they would have been a contraindication for blood donation.
c Current smokers in the control group were detected with cotinine measurement (see the text for details).
d Number of patients positive for the MHC allele or haplotype. Differences between ACS patients and controls had a P value of Ͻ0.05 for HLA-B*35 and a P value of Ͻ0.01 for HLA-DRB1*01; the rest of them were not significant, as described previously (30) . a Data are number of subjects (percentage) or number of subjects/total number of subjects studied (percentage). Numbers of subjects indicate the subjects who were positive for C. pneumoniae infection markers. For gender and smoking status, the number of subjects indicates the subjects who were positive for the any of the markers of C. pneumoniae infection. GMT, geometric mean titer; NA, not available; NS, not significant; -, not calculated. The value for C. pneumoniaespecific IgA, IgG, and IC was missing in one patient with ACS.
b Positive with any of the three markers of C. pneumoniae infection: IgA titer of Ն40, IgG titer of Ն128, or IC titer of Ն2.
c Current smokers and ex-smokers. d Current smokers (n ϭ 8) in controls were detected with cotinine measurement (see the text for details), and four of them were positive with any of the markers of C. pneumoniae infection. than in patients without these haplotypes (Table 3) . Also, any of the markers of C. pneumoniae infection were found significantly more frequently in patients with the HLA-A*03-B*35 or the HLA-A*03-B*35-LTAϩ724C haplotype than in patients with the HLA-DRB1*01 allele (P ϭ 0.044 and P ϭ 0.048, respectively). In subgroup analyses, when gender and smoking were also considered, any of the markers of C. pneumoniae infection were significantly associated with males having the HLA-A*03-B*35 (P ϭ 0.008) or HLA-A*03-B*35-LTAϩ724C (P ϭ 0.02) haplotype as well as with current smokers with these haplotypes or the HLA-B*35 allele alone (P ϭ 0.001, P ϭ 0.009, and P ϭ 0.003, respectively) ( Table 4 ). Among the controls, no associations between C. pneumoniae markers and MHC genes (Table 3) , smoking status, or gender were found.
In multiple-logistic regression analysis, any of the markers of C. pneumoniae infection were associated with HLA-B*35 (odds ratio [OR], 7.88; 95% confidence interval [CI], 2.44 to 25.43; P ϭ 0.0006) as well as with HLA-A*02 (OR, 4.15; 95% CI, 1.42 to 12.10; P ϭ 0.009) and C4B2 (OR, 3.60; 95% CI, 1.19 to 10.86; P ϭ 0.02). However, the latter two did not associate in univariate analyses.
DISCUSSION
This study shows for the first time that markers of C. pneumoniae infection are associated with HLA-B*35-related haplotypes in patients with ACS. Furthermore, among these patients, the prevalence of C. pneumoniae infection markers was a Value for C. pneumoniae-specific IgA, IgG, and IC were missing (n ϭ 1). Analyses were at the univariate level. NS, not significant. The total numbers of subjects who had HLA*03-B*35 in the diseased and control groups were 25 and 11, respectively (74 and 63 subjects did not have the allele, respectively); the total numbers of subjects who had LTAϩ724C in the diseased and control groups were 85 and 64, respectively (14 and 10 subjects did not have the allele, respectively); the total numbers of subjects who had HLA-A*03-B*35-LTAϩ724C in the diseased and control groups were 21 and 11, respectively (78 and 63 subjects did not have the allele, respectively); and the total numbers of subjects who had HLA-B*35 in the diseased and control groups were 35 and 14, respectively (64 and 60 subjects did not have the allele, respectively). more pronounced in smokers and males. In the controls, HLA-B*35 was not associated with C. pneumoniae infection. HLA-B*35 alone or together with the other functionally important genes on the A*03-B*35-LTAϩ724C haplotype may provide one possible link between CAD and C. pneumoniae infection.
C. pneumoniae infection has been linked to CAD by several methodological approaches, e.g., by seroepidemiological studies and by demonstrating the presence of C. pneumoniae in atherosclerotic lesions by culture, immunocytochemistry, PCR, and electron microscopy. In the present study, we used elevated antichlamydial IgA, IgG, and ICs as markers of chronic C. pneumoniae infection. Thus, antibodies are only indirect evidence of chronic Chlamydia infection; however, IC and IgA levels will not stay high without a continuous infection (25, 36) . The prevalence of these markers was lower than that reported previously (35) but significantly higher in patients than in controls. Smoking and male gender are established risk factors for CAD and also predispose one to C. pneumoniae infection (19, 22) . Also, in this study, male gender and smoking, when related to HLA-B*35, were definite risk factors for C. pneumoniae infection in patients with CAD. When HLA-B*35 was absent, any of the markers of C. pneumoniae infection were almost threefold lower in current smokers. No such relation was found in controls. Thus, suggested chronic C. pneumoniae infection in patients with CAD seems to be the result of multiple factors, and among them, the HLA-B*35-positive haplotype may play an important role.
Associations between immunity and genes regulating inflammation with CAD and C. pneumoniae infection have been studied only occasionally (29, 34) . Dahlén et al. (5) previously studied class II HLA genes and showed that C. pneumoniae antibodies and high Lp(a) levels were associated with HLA-DRB1*03 and HLA-DRB1*13, but the association was not later confirmed by the same group (5, 15) . We have recently shown an association between CAD and HLA- Both the incidence of CAD (16, 17) and the prevalence of C. pneumoniae markers (18) are elevated in the eastern part of Finland. The HLA-B*35 allele is one of the most frequently isolated HLA alleles in the Finnish population and has an even higher prevalence in the eastern parts (40) , suggesting an accessible association between CAD, C. pneumoniae, and the HLA-B*35 allele.
In addition to C. pneumoniae, an infectious etiology of atherosclerosis and CAD has been implicated with regard to Helicobacter pylori, herpes simplex virus, and cytomegalovirus (27) . Several case control studies suggested that vaccination against influenza virus may reduce the risk of myocardial infarction (8, 26) . One of the preferred alleles in the influenza A virus-specific cytotoxic-T-lymphocyte response is HLA-B*3501; preferential HLA usage is dependent on the type of the virus and determines differential cytokine expression (2, 3) . The HLA-B*35 allele has also been associated with chronic hepatitis B virus, hepatitis C virus, and herpes simplex virus infections; Epstein-Barr virus seropositivity; and cytotoxic responses against Aspergillus and Mycobacterium tuberculosis (10, 20, 33, 45) . In human immunodeficiency virus infection, the rapid progression of the disease has been correlated to the interaction of a virus peptide with B*35 (4) . Recently, it has been shown that C. pneumoniae-infected host cells can induce genes involved in apoptosis (6) , while HLA-B35 influences the apoptosis rate (37) .
The results of our study indicate that HLA-B35 presents C. pneumoniae peptides and may further provide an environment that predetermines the establishment of persistent C. pneumoniae infection. The HLA-B*35 allele has been shown to confer a significant proapoptotic influence to different kind of cells. It may promote pathological cell activation and proliferation and gene transcription through the control of the intracellular cation concentration (38) . C. pneumoniae-infected monocyte cells are shown to up-regulate many genes including the vasoconstrictor endothelin 1 (41) . HLA-B*35 influences the upregulation of endothelin 1, providing an explanation for the epidemiological association existing between isolated pulmonary hypertension and HLA-B*35 (38) .
In conclusion, our results show that the HLA-B*35-positive haplotypes confer a C. pneumoniae-related risk for CAD.
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